The cholesterol medication alirocumab, a PCSK9 inhibitor, combined with a statin appeared to reduce LDL cholesterol levels by more than 50% among patients after a heart transplant, according to a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.
PCSK9 inhibitor combined with a statin may help reduce LDL cholesterol after heart transplant
- Thread starter Educator
- Start date